John Fry - Aligos Therapeutics Ex Devel
| ALGS Stock | USD 25.51 2.52 10.96% |
Insider
John Fry is Ex Devel of Aligos Therapeutics
| Age | 61 |
| Address | One Corporate Drive, South San Francisco, CA, United States, 94080 |
| Phone | 800 466 6059 |
| Web | https://www.aligos.com |
John Fry Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Fry against Aligos Therapeutics stock is an integral part of due diligence when investing in Aligos Therapeutics. John Fry insider activity provides valuable insight into whether Aligos Therapeutics is net buyers or sellers over its current business cycle. Note, Aligos Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aligos Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Fry over six months ago Acquisition by John Fry of 205 shares of VTv Therapeutics at 0.8262 subject to Rule 16b-3 |
Aligos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6732) % which means that it has lost $0.6732 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4669) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, Aligos Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 14.9 M in 2024, despite the fact that Other Assets are likely to grow to (2.3 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Lieping MD | NextCure | 67 | |
| Angela MD | Spero Therapeutics | N/A | |
| David Hanley | Nuvation Bio | 54 | |
| Dr IV | Assembly Biosciences | 52 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Michele Anderson | Assembly Biosciences | N/A | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| Sandeep MD | Instil Bio | 55 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Bronson Crouch | Instil Bio | 51 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.67 |
Aligos Therapeutics Leadership Team
Elected by the shareholders, the Aligos Therapeutics' board of directors comprises two types of representatives: Aligos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aligos. The board's role is to monitor Aligos Therapeutics' management team and ensure that shareholders' interests are well served. Aligos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aligos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonid Beigelman, Pres Director | ||
| Dr DABT, Executive Sciences | ||
| Dr MBA, President CEO | ||
| Kristina Engeseth, Ex Culture | ||
| Lucinda JD, Chief VP | ||
| John Fry, Ex Devel | ||
| TseI Lin, VP Head | ||
| Lesley CPA, Executive CFO | ||
| Hardean MD, Chief Officer | ||
| Julian DPHIL, Executive Officer | ||
| Matthew MD, Executive Officer | ||
| David Smith, Executive Operations |
Aligos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aligos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.67 | ||||
| Operating Margin | (15.86) % | ||||
| Current Valuation | 25.74 M | ||||
| Shares Outstanding | 3.46 M | ||||
| Shares Owned By Insiders | 17.79 % | ||||
| Shares Owned By Institutions | 48.80 % | ||||
| Number Of Shares Shorted | 291.5 K | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 14.74 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.